BridgeMD
New treatment option for Locally Advanced Pancreatic Ductal Adenocarcinoma
Official title PULSAR in Systemic Therapy for Pancreatic Cancer
ClinicalTrials.gov ID: NCT07269626
What this study is testing
- What it's testing
- Pancreatic cancer remains one of the malignancies with the lowest survival rates, largely due to late-stage diagnosis and the difficulty of achieving curative resection. A substantial proportion of patients present with locally advanced, unresectable disease at the time of diagnosis, making intensive systemic therapy the current standard of care.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 19 and older
You may be able to join if
- Age ≥ 19 years.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
- Histologically confirmed pancreatic ductal adenocarcinoma.
- Disease extent classified as borderline resectable, locally advanced, or oligometastatic disease (defined as ≤ 3 metastatic lesions) at the time of...
- Completion of at least 2-4 cycles of first-line systemic therapy (FOLFIRINOX, gemcitabine/nab-paclitaxel, or NALIRIFOX) without evidence of distant...
You likely can't join if
- Pregnant or breastfeeding women.
- Presence of brain metastases or leptomeningeal disease.
- History of prior radiotherapy to the intended treatment area.
- Significant comorbid conditions that may interfere with study participation or the ability to safely receive study treatment, as determined by the...
- Patients deemed unlikely to comply with study procedures or follow-up requirements.
- Any condition that, in the opinion of the principal investigator or treating physician, makes the patient inappropriate for participation in this...
See the full eligibility criteria
- Age ≥ 19 years.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
- Histologically confirmed pancreatic ductal adenocarcinoma.
- Disease extent classified as borderline resectable, locally advanced, or oligometastatic disease (defined as ≤ 3 metastatic lesions) at the time of staging evaluation.
- Completion of at least 2-4 cycles of first-line systemic therapy (FOLFIRINOX, gemcitabine/nab-paclitaxel, or NALIRIFOX) without evidence of distant progression.
- Presence of a lesion suitable for radiotherapy, as determined by the investigator, and measurable disease per RECIST 1.1 criteria.
- Ability to understand the study requirements and voluntarily provide written informed consent.
- Pregnant or breastfeeding women.
- Presence of brain metastases or leptomeningeal disease.
- History of prior radiotherapy to the intended treatment area.
- Significant comorbid conditions that may interfere with study participation or the ability to safely receive study treatment, as determined by the investigator (e.g., uncontrolled infection, congestive heart failure...
- Patients deemed unlikely to comply with study procedures or follow-up requirements.
- Any condition that, in the opinion of the principal investigator or treating physician, makes the patient inappropriate for participation in this trial.
The study team makes the final eligibility decision.
Where it's taking place
- Seoul, Select Province/State, South Korea
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 19 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Seoul, Select Province/State, South Korea. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.